The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling

Blood

Volumn 127, Issue 11, 2016, Pages 1438-1448

  Flori, Michael ^a   Schmid, Corina A ^a   Sumrall, Eric T ^a   Tzankov, Alexandar ^b   Law, Charity W ^a,c   Robinson, Mark D ^a,c   Müller, Anne ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Program in Molecular Life Sciences   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; ONCOPROTEIN; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN; S1PR2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE LOCUS; GENE SILENCING; GERMINAL CENTER; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; S1PR2 GENE; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CLASSIFICATION; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MOUSE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; GTP-BINDING PROTEIN ALPHA SUBUNITS, G12-G13; HETEROGRAFTS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LYSOSPHINGOLIPID; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84962519881     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-662635     Document Type: Article

References (27)

1. Wlodarska I, Veyt E, De Paepe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia. 2005;19(8):1299-1305.
2. Haralambieva E, Adam P, Ventura R, et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia. 2006;20(7):1300-1303.
3. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T (3;14) (p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19(4):652-658.
4. Rouhigharabaei L, Finalet Ferreiro J, Tousseyn T, et al. Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1. PLoS One. 2014;9(1):e85851.
5. Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology. 2010;57(1):73-80.
6. Brown PJ, Ashe SL, Leich E, et al. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood. 2008;111(5):2816-2824.
7. Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011;117(23):6227-6236.
8. Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Müller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia. 2012;26(11):2421-2424.
9. Sagaert X, de Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosaassociated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(16):2490-2497.
10. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood. 2004;104(9):2933-2935.
11. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2005;11(3):1065-1072.
12. Tzankov A, Leu N, Muenst S, et al. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. J Hematol Oncol. 2015;8:70.
13. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-5502.
14. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-2113.
15. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207.
16. Hu H, Wang B, Borde M, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol. 2006;7(8):819-826.
17. Sagardoy A, Martinez-Ferrandis JI, Roa S, et al. Downregulation of FOXP1 is required during germinal center B-cell function. Blood. 2013;121(21):4311-4320.
18. Wong KK, Gascoyne DM, Brown PJ, et al. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia. 2014;28(2):362-372.
19. van Keimpema M, Grüneberg LJ, Mokry M, et al. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kB to promote survival of human B cells. Blood. 2014;124(23):3431-3440.
20. Gabut M, Samavarchi-Tehrani P, Wang X, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell. 2011;147(1):132-146.
21. Xu-Monette ZY, Møller MB, Tzankov A, et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;122(15):2630-2640.
22. Frei E, Visco C, Xu-Monette ZY, et al. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol. 2013;66(11):956-961.
23. Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
24. Jourdan M, Caraux A, De Vos J, et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 2009;114(25):5173-5181.
25. Worzfeld T, Wettschureck N, Offermanns S. G (12)/G (13)-mediated signalling in mammalian physiology and disease. Trends Pharmacol Sci. 2008;29(11):582-589.
26. Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via Ga13 in germinal centre B-cellderived lymphoma. Nature. 2014;516(7530):254-258.
27. Cattoretti G, Mandelbaum J, Lee N, et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 2009;69(22):8686-8692.